Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Lung Cancer Non-Small Cell Cancer (NSCLC)
Real-World Immuno-Radiotherapy for Advanced NSCLC
The optimal combination strategy for radiotherapy combined with immunotherapy (iRT) in advanced non-small-cell lung cancer (NSCLC) remains unclear, and there is a lack of real-world data to validate its efficacy.
- Trial name
- OCEANUS (NCT06747026)
- Testing
- initial Sequential iRT, initial Concurrent iRT, RT with maintenance of ICI
- Where
- Hong Kong
- Volunteers
- 338 people
- Sponsor
- Fengming Kong
Small Cell Lung Carcinoma
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer
As the gene polymorphism of uridine diphosphate glucuronosyl transferase 1A1(UGT1A1)is related to the side effect of diarrhea induced by irinotecan.
- Trial name
- TDICC (NCT01977235)
- Testing
- Irinotecan, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 110 people
- Sponsor
- Third Military Medical University
Carcinoma, Non-Small-Cell Lung, Neoplasms
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
The study is primarily designed to assess the safety and tolerability of escalating oral doses of Debio 1143 and preliminary anti-tumour activity when combined with the standard dose of avelumab in participants with advanced…
- Trial name
- NCT03270176
- Testing
- Debio 1143, Avelumab
- Where
- 9 sites in Canada, Poland and 1 more
- Volunteers
- 54 people
- Sponsor
- Debiopharm International SA
Lung Cancer
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have relapsed or…
- Trial name
- NCT00022711
- Testing
- temozolomide
- Where
- 17 sites in United States
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
This study is a randomized phase III trial that aiming to investigate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) guided hypofractionated radiotherapy (hypo-RT) in patients with locally advanced…
- Trial name
- NCT06545747
- Testing
- DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT, Concurrent chemotherapy
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
This is a phase II, prospective, multi-centre study. To assess the efficacy and safety of furmonertinib in patients with epidermal growth factor receptor 20ins mutation positive stage IB-IIIA Non-small Cell Lung Carcinoma…
- Trial name
- NCT06192849
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Juan LI, MD
Lung Cancer
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084799
- Testing
- monoclonal antibody hu3S193
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ludwig Institute for Cancer Research
Lung Cancer, Metastatic Cancer
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain function (the ability to think, learn, remember, and judge) in patients with non-small cell lung cancer and brain metastases.
- Trial name
- NCT00385398
- Testing
- erlotinib hydrochloride, temozolomide, stereotactic radiosurgery
- Sponsor
- University of Medicine and Dentistry of New Jersey
Lung Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC)
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma
The goal of this clinical trial is to learn if adding intermittent hypoxic training (IHT) to standard neoadjuvant chemo-immunotherapy can increase the pathologic complete response (pCR) rate in patients aged 18 to 75 of both…
- Trial name
- NCT07618793
- Testing
- Intermittent Hypoxic Training (IHT), Standard Neoadjuvant Chemo-immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- zhang yi
Ovarian Cancer, Renal Cancer
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
The primary objectives of this Phase 1b/2 study were as follows: Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or…
- Conditions
- Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT00531284
- Testing
- Carfilzomib, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Amgen
Lung Cancer, Lymphoma
Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound
Aim: To investigate whether the novel 3rd generation FNB needle provides a better diagnostic accuracy than a standard FNA needle in EUS-B guided diagnosis of common deep seated thoracic malignancies (lung cancer and lymphoma).
- Conditions
- Lung Cancer, Lymphoma, Sarcoidosis
- Trial name
- IMPROVED (NCT06848738)
- Testing
- FNB, FNA
- Where
- 3 sites in Denmark
- Volunteers
- 362 people
- Sponsor
- Zealand University Hospital
Carcinoma, Non-Small-Cell Lung
Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is an open-label, multicenter, multiple-dose, Phase I-II study of CHR-2797 co-administered with erlotinib in patients with histologically or pathologically confirmed Stage IIIB (with pleural effusion), Stage IV, or recurrent…
- Trial name
- NCT00522938
- Testing
- CHR-2797 (tosedostat), erlotinib
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Chroma Therapeutics
Lung Cancers, Radiation Treatment for Tumors
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
The purpose of this study was to evaluate the effect of immunotherapy combined with spatial fractionation radiotherapy and low dose radiotherapy on the prognosis of patients with advanced lung cancer under specific dose regimens…
- Trial name
- NCT06775678
- Testing
- Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy, Conventional fractionated radiotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Relapsed/Refractory Small Cell Lung Cancer
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
The main aim of this study is to: evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only evaluate anti-tumor…
- Trial name
- DeLLphi-301 (NCT05060016)
- Testing
- Tarlatamab
- Where
- 80 sites in United States, Austria and 16 more
- Volunteers
- 222 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
- Trial name
- NCT00230126
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Small Cell Lung Cancer, Brain Metastases, Adult
Tarlatamab for SCLC Brain Metastases
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
- Trial name
- T-BRAIN (NCT07402343)
- Testing
- Tarlatamab
- Where
- 4 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- Maastricht University Medical Center
Non-Small Cell Lung Cancer (NSCLC)
An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin
This is an open-label dose escalation trial using ABI-007 plus carboplatin.
- Trial name
- NCT00274443
- Testing
- ABI-007 (Abraxane) and Carboplatin
- Where
- Russia
- Volunteers
- 250 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will…
- Conditions
- Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M
- Trial name
- NCT03532698
- Testing
- Aspirin, Osimertinib
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non Small Cell Lung Cancer
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR and tumor cell proliferation related kinase c-Kit…
- Trial name
- NCT04619563
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
Small Cell Lung Cancer
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one subtypes.
- Trial name
- NCT01417806
- Testing
- Topotecan and Pasireotide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- South Florida Veterans Affairs Foundation for Research and Education
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.